Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors - PubMed
5 hours ago
- #bispecific antibodies
- #solid tumors
- #cancer immunotherapy
- Combination therapy uses a CD2-targeted bispecific antibody to improve CD3 T cell engager (TCE) treatment for solid tumors.
- The HER2×CD2 bispecific provides tumor-dependent costimulation, enhancing TCE efficacy and reducing toxicity.
- It restores anti-tumor activity at low TCE doses, preventing TCE-driven toxicity while maintaining effectiveness.
- In a xenograft model, co-treatment with HER2×CD2 led to complete tumor remission in 8 of 9 mice, compared to 1 of 9 with TCE alone.
- HER2×CD2 compensates for loss of CD58 on tumor cells, a common immune escape mechanism.
- Unlike CD28-based costimulation, it activates CD28-negative CD8 T cells, important in elderly patients and solid tumors.
- HER2×CD2 induces lower cytokine release than a HER2×CD28 bispecific while providing comparable anti-tumor benefits.